OTCMKTS:NPHC Nutra Pharma (NPHC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Nutra Pharma Stock (OTCMKTS:NPHC) 30 days 90 days 365 days Advanced Chart Get Nutra Pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume457,628 shsMarket Capitalization$710 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Nutra Pharma Corporation is a development-stage medical technology company focusing on the research and development of therapeutic products for gastrointestinal disorders, notably those arising from opioid use. The company is advancing a portfolio of proprietary formulations designed to address opioid-induced constipation (OIC), a common side effect of pain management regimens. Its lead candidate, RIMSO-50, is an oral solution being evaluated for its potential to alleviate OIC by promoting bowel movements without compromising the effectiveness of opioid analgesics. Nutra Pharma is leveraging its in-house formulation capabilities and preclinical data to support ongoing regulatory submissions and potential partner collaborations. Nutra Pharma holds patent protection in key jurisdictions, including the United States, Europe and Israel, covering its novel formulations and methods of use. The company’s intellectual property strategy is aimed at securing market exclusivity and facilitating potential licensing agreements. Headquartered in Tel Aviv, Israel, Nutra Pharma is building its operational footprint with activities in North America and Europe. While the company remains in the clinical and regulatory phase, it seeks to advance its product pipeline through strategic partnerships and capital investment to bring its therapies to patients in need.AI Generated. May Contain Errors. Read More Receive NPHC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nutra Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NPHC Stock News HeadlinesNutra Pharma Corp (NPHC)April 9, 2025 | uk.investing.comPharmaNutra SpA: Strong Sales Growth and International Expansion Reinforce Buy RatingSeptember 11, 2024 | markets.businessinsider.comElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.September 10 at 2:00 AM | Banyan Hill Publishing (Ad)Biscuit brand Britannia forays into healthtech with NutriPlus appApril 3, 2024 | msn.comNutra Pharma Corp. Reaches Settlement with SECMarch 22, 2024 | globenewswire.comCollegium PharmaceuticalMarch 3, 2024 | forbes.comNutra Pharma Corp.February 21, 2024 | wsj.comNutri Pharmaceuticals Research Inc.October 7, 2023 | barrons.comSee More Headlines NPHC Stock Analysis - Frequently Asked Questions How were Nutra Pharma's earnings last quarter? Nutra Pharma Corp. (OTCMKTS:NPHC) released its quarterly earnings data on Friday, August, 17th. The company reported $0.00 EPS for the quarter. The company earned $0.03 million during the quarter. How do I buy shares of Nutra Pharma? Shares of NPHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nutra Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nutra Pharma investors own include SMART Global (SGH), Jumia Technologies (JMIA), America First Multifamily Investors (ATAX), Prospect Capital (PSEC), Tilray Brands (TLRY), AGNC Investment (AGNC) and Akoustis Technologies (AKTS). Company Calendar Last Earnings8/17/2018Today9/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:NPHC CIK1119643 Webwww.nutrapharma.com Phone(954) 509-0911Fax877-895-5647Employees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$440 thousand Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.08 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares7,099,740,000Free Float2,733,400,000Market Cap$710 thousand OptionableNot Optionable Beta-0.21 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:NPHC) was last updated on 9/10/2025 by MarketBeat.com Staff From Our Partners“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nutra Pharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nutra Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.